COMPARATIVE STUDIES OF BETA-BLOCKER CONSUMPTION IN UKRAINE AND SOME EUROPEAN COUNTRIES
DOI:
https://doi.org/10.11603/2312-0967.2025.1.15272Keywords:
arterial hypertension, β-blockers, consumption volumes, reimbursement, ATC/DDD methodology, pharmaceutical marketAbstract
The aim of the work. Analysis of the dynamics of drug consumption in the β-blocker group in Ukraine (for 2021-2023) and comparison of consumption indicators with data from European countries - Estonia and Norway.
Materials and Methods. The study was conducted using data from the State Register of Medicinal Products of Ukraine and the analytical system for pharmaceutical market research "Proxima Research" by the company "Morion." The consumption analysis of the studied drugs was carried out using the ATC/DDD methodology recommended by the WHO. DDDs per 1,000 inhabitants per day (DID) was used as the unit of measurement.
Results and Discussion. It was found that the total consumption of β-blocker monodrugs in Ukraine increased from 22.551 DID in 2021 to 25.373 DID in 2023. The highest consumption volumes among β-blocker monodrugs were for bisoprolol (14.749 DID in 2021 to 16.104 DID in 2023). High consumption volumes were found for nebivolol (3.605 DID in 2021 to 4.374 DID in 2023) and carvedilol (2.37 DID in 2021 to 2.424 DID in 2023). The consumption of fixed combinations of β-blockers ranged from 1.11-1.14 DID.
In the studied European countries, unlike in Ukraine, metoprolol ranks first in terms of consumption volumes: it accounts for 48% of total β-blocker consumption in Estonia and 71% in Norway. In Ukraine, during the period of 2022-2023, there was a sharp increase in metoprolol consumption by 98.6 %.
Conclusions. The study identified the characteristics of β-blocker consumption in Ukraine from 2021 to 2023. A trend of increasing overall consumption was observed in 2023, showing a 12.51 % rise compared to 2021. The highest consumption of bisoprolol, significant consumption levels of nebivolol and carvedilol, as well as the sharp increase in metoprolol consumption, are associated with the clinical efficacy and safety of these drugs. Additionally, the economic affordability of bisoprolol, carvedilol, and metoprolol for the population, including their reimbursement under Program of state guarantees of medical care for the population contributed to this trend.
References
Mancia G, Kreutz R, Brunström M, et al. The Task Force for the management of arterial hypertension of the European society of hypertension. 2023 ESH guidelines for the management of arterial hypertension. Endorsed by the European renal association (ERA) and the International society of hypertension (ISH). J Hypertens. 2023;41(12):1874–2071. DOI: 10.1097/HJH.0000000000003480 DOI: https://doi.org/10.1097/HJH.0000000000003480
Williams B, Mancia G, Spiering W, et al. 2018 Practice guidelines for the management of arterial hypertension of the European society of hypertension and the European society of cardiology: ESH/ESC task force for the management of arterial hypertension. J Hypertens. 2018;36(12):2284–2309. DOI: 10.1097/HJH.0000000000001961. DOI: https://doi.org/10.1097/HJH.0000000000001961
Stoschitzky K. Differences between beta-blockers in the treatment of arterial hypertension. Journal of Hypertension. 2021;39(2):384-385. DOI: 10.1097/HJH.0000000000002722 DOI: https://doi.org/10.1097/HJH.0000000000002722
Mahfoud F, Wang J, Ray S.The current position of b-blockers in hypertension: guidelines and clinical practice. Current medical research and opinion. 2024;40(1):25-32. DOI: 10.1080/03007995.2024.2318003 DOI: https://doi.org/10.1080/03007995.2024.2318003
Messerli FH, Bangalore S, Mandrola JM. Β-blockers switched to first-line therapy in hypertension. Lancet. 2023;402(10414):1802–1804. DOI: 10.1016/S0140-6736(23)01733-6. DOI: https://doi.org/10.1016/S0140-6736(23)01733-6
Srinivasan AV. Propranolol: a 50-year historical perspective. Ann Indian Acad Neurol. 2019;22(1):21-26. DOI: 10.4103/aian.AIAN_201_18. DOI: https://doi.org/10.4103/aian.AIAN_201_18
Derzhavnyy reyestr likarskykh zasobiv Ukrainy. Available from: http://www.drlz.com.ua/
Malanchuk, N. V., Demchuk, M. B., Pokotylo, O. O., et al. The comparative analysis of the economic availability of antihypertensives from the group of beta-blockers in Ukraine. Social Pharmacy in Health Care, 2024.10(1):42–51. DOI: 10.24959/sphhcj.24.315 DOI: https://doi.org/10.24959/sphhcj.24.315
Order No. 1495, 21.08.2023, Ministry of Health of Ukraine. On approval of the Register of medicines and medical devices subject to reimbursement under the program of state guarantees of medical care for the population. Available from: https://zakon.rada.gov.ua/rada/show/v1495282-23#Text.
АТС/DDD Index Tsentru VOOZ z metodolohii statystychnykh doslidzhen LZ. Available from: https://www.whocc.no/atc_ddd_index/
World Health Organization. DDD Indicators. Available from: http://www.who.int/medicines/regulation/ medicines - safety/toolkit_ indicators/en/.
Ukraine Population Growth Rate 1950-2025. Available from: https://www.macrotrends.net/global-metrics/countries/UKR/ukraine/population-growth-rate].
Estonian Statistics on Medicines; 2022-2023. Available from: https://ravimiamet.ee/sites/default/files/documents/2024-11/Ravimiamet_aastaraamat_2024.pdf
Drug Consumption in Norway 2019-2023. Data from Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database. Available from: https://www.fhi.no/contentassets/b0802ad9303347b682cf6a8fa701ec91/legemiddelforbruket-i-norge-2019-2023-rapport-2024.pdf
Taddei S, Tsabedze N, Tan R. β -blockers are not all the same: pharmacologic similarities and differences, potential combinations and clinical implications. Current medical research and opinion. 2024;40(1):15-23. DOI: 10.1080/03007995.2024.2318058 DOI: https://doi.org/10.1080/03007995.2024.2318058
Marti HP, Lopez A, Schwartzmann P. Safety and tolerability of b-blockers: importance of cardioselectivity. Current medical research and opinion. 2024;40(1):55-62. DOI: 10.1080/03007995.2024.2317433 DOI: https://doi.org/10.1080/03007995.2024.2317433
Park Y, Choi BG, Rha S, et al. Selective ß1-blockers are not associated with new-onset diabetes mellitus in hypertensive patients. J Cardiovasc Pharmacol. 2018;71(1):38-45. DOI: 10.1097/FJC.0000000000000543. DOI: https://doi.org/10.1097/FJC.0000000000000543
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Pharmaceutical Review / Farmacevtičnij časopis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
